Johnson & Johnson Receivables 2012-2026 | JNJ
Johnson & Johnson receivables from 2012 to 2026. Receivables can be defined as the total amount of collectibles for a company
- Johnson & Johnson receivables for the quarter ending March 31, 2026 were $17.178B, a 15.74% increase year-over-year.
- Johnson & Johnson receivables for 2025 were $17.178B, a 15.74% increase from 2024.
- Johnson & Johnson receivables for 2024 were $14.842B, a 0.21% decline from 2023.
- Johnson & Johnson receivables for 2023 were $14.873B, a 5.94% increase from 2022.
|
Johnson & Johnson Annual Receivables (Millions of US $) |
|
|---|---|
| 2025 | $17,178 |
| 2024 | $14,842 |
| 2023 | $14,873 |
| 2022 | $14,039 |
| 2021 | $15,283 |
| 2020 | $13,576 |
| 2019 | $14,481 |
| 2018 | $14,098 |
| 2017 | $13,490 |
| 2016 | $11,699 |
| 2015 | $10,734 |
| 2014 | $10,985 |
| 2013 | $11,713 |
| 2012 | $11,309 |
| 2011 | $10,581 |
|
Johnson & Johnson Quarterly Receivables (Millions of US $) |
|
|---|---|
| 2025-12-31 | $17,178 |
| 2025-09-30 | $17,611 |
| 2025-06-30 | $17,846 |
| 2025-03-31 | $16,020 |
| 2024-12-31 | $14,842 |
| 2024-09-30 | $16,174 |
| 2024-06-30 | $15,794 |
| 2024-03-31 | $14,946 |
| 2023-12-31 | $14,873 |
| 2023-09-30 | $14,798 |
| 2023-06-30 | $16,777 |
| 2023-03-31 | $16,350 |
| 2022-12-31 | $14,039 |
| 2022-09-30 | $15,890 |
| 2022-06-30 | $16,139 |
| 2022-03-31 | $15,594 |
| 2021-12-31 | $15,283 |
| 2021-09-30 | $14,911 |
| 2021-06-30 | $14,871 |
| 2021-03-31 | $14,938 |
| 2020-12-31 | $13,576 |
| 2020-09-30 | $14,579 |
| 2020-06-30 | $14,645 |
| 2020-03-31 | $14,874 |
| 2019-12-31 | $14,481 |
| 2019-09-30 | $14,801 |
| 2019-06-30 | $14,653 |
| 2019-03-31 | $14,115 |
| 2018-12-31 | $14,098 |
| 2018-09-30 | $14,048 |
| 2018-06-30 | $14,111 |
| 2018-03-31 | $14,166 |
| 2017-12-31 | $13,490 |
| 2017-09-30 | $13,155 |
| 2017-06-30 | $13,283 |
| 2017-03-31 | $12,300 |
| 2016-12-31 | $11,699 |
| 2016-09-30 | $11,798 |
| 2016-06-30 | $12,062 |
| 2016-03-31 | $11,406 |
| 2015-12-31 | $10,734 |
| 2015-09-30 | $11,366 |
| 2015-06-30 | $11,968 |
| 2015-03-31 | $11,533 |
| 2014-12-31 | $10,985 |
| 2014-09-30 | $11,615 |
| 2014-06-30 | $12,257 |
| 2014-03-31 | $12,116 |
| 2013-12-31 | $11,713 |
| 2013-09-30 | $12,027 |
| 2013-06-30 | $11,614 |
| 2013-03-31 | $11,515 |
| 2012-12-31 | $11,309 |
| 2012-09-30 | $11,175 |
| 2012-06-30 | $10,992 |
| 2012-03-31 | $10,982 |
| 2011-12-31 | $10,581 |
| 2011-09-30 | $10,552 |
| 2011-06-30 | $10,982 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |